Drug intelligence / Profile preview

sNinj1-NP

Development stage
Preclinical
Lead developer
Asahikawa Medical University
Modality
Peptides, Nanoparticles → Drug Delivery Systems
Administration
Intraperitoneal
01

Overview

sNinj1-NP is a sustained-release nanoparticle formulation of a soluble ninjurin-1 (sNinj1)-mimetic peptide encapsulated in poly(lactic-co-glycolic acid) (PLGA) microspheres. Developed by researchers at Asahikawa Medical University, sNinj1-NP mimics the cleaved extracellular domain of Ninjurin-1 (sNinj1) to exert anti-inflammatory and endothelial-protective effects. It competitively inhibits the homophilic adhesion and oligomerization of membrane-bound Ninjurin-1 (Ninj1), thereby suppressing macrophage activation, reducing the expression of pro-inflammatory cytokines (such as IL-6 and IL-1β), and preserving endothelial nitric oxide synthase (eNOS) expression. In preclinical models of cecum ligation puncture (CLP)-induced sepsis, sNinj1-NP administration significantly improved survival rates and attenuated sepsis-induced kidney dysfunction and acute kidney injury.

Other names
soluble ninjurin-1 nanoparticlessustained-release soluble ninjurin-1 nanoparticles
02

Targets

NINJ1 (Ninjurin-1)

Beyond the preview

Go deeper on sNinj1-NP.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on sNinj1-NP.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call